Company profile: Avalo Therapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage biopharmaceutical therapies developing monoclonal antibodies and a fusion protein for inflammatory diseases, including AVTX-009 (anti-IL-1β), quisovalimab (anti-LIGHT), AVTX-008 (BTLA agonist fusion protein), and AVTX-002 (fully human anti-LIGHT, in Phase 2 for non-eosinophilic asthma, inflammatory bowel diseases, and COVID-19 acute respiratory distress syndrome).
Products and services
- AVTX-002: A fully human monoclonal antibody directed against human LIGHT, Phase 2 for non-eosinophilic asthma, inflammatory bowel diseases, and COVID-19 acute respiratory distress syndrome
- Quisovalimab: An anti-LIGHT monoclonal antibody in development for various inflammatory conditions, targeting LIGHT involved in inflammatory responses across multiple disease areas
- AVTX-009: An anti-IL-1β monoclonal antibody targeting inflammatory diseases by engaging the IL-1β pathway implicated in inflammation across disease contexts
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Avalo Therapeutics
Cyxone
HQ: Sweden
Website
- Description: Provider of biopharmaceutical R&D focused on cyclotide-based drugs for severe autoimmune diseases. Operates via an international expert network across research, development and manufacturing. Pipeline includes Rabeximod, an oral Phase 2 candidate for rheumatoid arthritis targeting inflammatory macrophages, and T20K, an early clinical candidate for multiple sclerosis modulating T cell activity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cyxone company profile →
Phadia
HQ: Sweden
Website
- Description: Provider of complete blood test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; develops, manufactures and markets these systems, with more than 40 years of leadership in allergy testing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Phadia company profile →
BioAtla
HQ: United States
Website
- Description: Provider of conditionally active biologics (CABs) for cancer-targeted therapeutics activated under specific physiological conditions; the CIAO! platform for antibody optimization; CAB-ADCs, CAB-CAR-T, and CAB-Bispecifics to improve safety and efficacy; and Mecbotamab Vedotin, a CAB-AXL-ADC for AXL-expressing tumors evaluated in sarcoma and NSCLC.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioAtla company profile →
Viridian Therapeutics
HQ: United States
Website
- Description: Provider of treatments for patients suffering from diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Viridian Therapeutics company profile →
Ampio Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies targeting inflammatory conditions, including OA-201, a small molecule formulation explored as a potential treatment for osteoarthritis of the knee and other joints.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ampio Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Avalo Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Avalo Therapeutics
2.2 - Growth funds investing in similar companies to Avalo Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Avalo Therapeutics
4.2 - Public trading comparable groups for Avalo Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →